Initial use of voriconazole positively affects outcome of Candida parapsilosis bloodstream infection: a retrospective analysis

• Published in: Translational pediatrics 2020-08, Vol.9 (4), p.480-486
• Main Authors: Wu, Yejuan, Wei, Dong, Gong, Xiaohui, Shen, Yunlin, Zhu, Yingying, Wang, Junfang, Gao, Zhen
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2224-4344; 2224-4336; 2224-4344
• DOI: 10.21037/tp-20-37

Concerns have arisen regarding the optimal antifungal regimen for ( ) bloodstream infection (BSI) in view of its reduced sensitivity to fluconazole. The clinical characteristics of 58 BSI newborns who received treatment between June 2014 to December 2018 in the Shanghai Children's Hospital were retrospectively analyzed. Based on the initial antifungal drugs, these patients were divided into fluconazole group (n=30) and voriconazole group (n=21). After 7-10-day treatment, the antifungal drugs were replaced if blood culture still showed positive. The clinical characteristics and therapeutic effects were compared between two groups. There were no significant differences in the clinical characteristics between two groups (P>0.05). The median time to a negative culture in the voriconazole group was 7 [interquartile range (IQR), 6-10] days, which was significantly shorter than in the fluconazole group [9 (IQR, 7-18.5) days; P=0.034]. The overall median time to a negative culture was 8 days. After 8-day antifungal therapy, in the voriconazole group and fluconazole group, negative culture was observed in 16 and 12 patients, respectively; the positive culture was noted in 5 and 16 patients, respectively; the effective rate was 76.1% and 40%, respectively, showing marked difference (χ =6.535, P=0.011). None died in the voriconazole group, but 4 died in the fluconazole group. The median time of treatment for fungal sepsis in the voriconazole group was 22 (IQR, 20-26) days, which was significantly shorter than in the fluconazole group [32 (IQR, 23.5-40) days; P=0.000]. The initial clinical manifestations of BSI vary among individuals, and voriconazole is superior to fluconazole in the treatment of BSI.